Roche identifies disease areas addressed in collaboration with Genmab
11 Dec 2006 -
Genmab A/S announced that the company's partner Roche has named the disease areas for the antibody programs developed with Genmab. These include inflammation, oncology, respiratory and vascular diseases. The antibodies are primarily at the pre-clinical stage with one in Phase I development. The development of one of the programs is carried out in collaboration with Genentech, where Roche owns a majority
stake.
Top
Contact
Print version
PDF version
Send article
RSS feed